Type II collagen oral tolerance; mechanism and role in collagen-induced arthritis and rheumatoid arthritis

References

• Faiia AM, Weiner HL. Oral tolerance. Immunol Rev. 2005;206: 232–59.
   PubMed Web of Science ®Google Scholar
• Mayer L, Shao L. Therapeutic potential of oral tolerance. Nat Rev Immunol. 2004;4(6):407–19.
   PubMed Web of Science ®Google Scholar
• Mowat AM. Anatomical basis of tolerance and immunity to intestinal antigens. Nat Rev Immunol. 2003;3(4):331–41.
   PubMed Web of Science ®Google Scholar
• Fujihashi K, Dohi T, Rennert PD, Yamamoto M, Koga T, Kiyono H, et al. Peyer's patches are required for oral tolerance to pro-teins. Proc Natl Acad Sci USA. 2001;98(6):3310–5.
   PubMed Web of Science ®Google Scholar
• Takayama N, Igarashi 0, Kweon MN, Kiyono H. Regulatory role of Peyer's patches for the inhibition of OVA-induced allergic diarrhea. Clin Immunol. 2007;123(2):199–208.
   Google Scholar
• Williamson E, Bilsborough JM, Viney JL. Regulation of mucosal dendritic cell function by receptor activator of NF-kappa B (RANK)/RANK ligand interactions: impact on tolerance induc-tion. J Immunol. 2002;169(7):3606–12.
   Google Scholar
• Spahn TW, Fontana A, Faria AM, Slavin AJ, Eugster HP, Zhang X, et al. Induction of oral tolerance to cellular immune responses in the absence of Peyer's patches. Eur J Immunol. 2001; 31(4):1278–87.
   PubMed Web of Science ®Google Scholar
• Friedman A, Weiner HL. Induction of anergy or active suppres-sion following oral tolerance is determined by antigen dosage. Proc Natl Acad Sci USA. 1994;91(14):6688–92.
   PubMed Web of Science ®Google Scholar
• Coombes JL, Powrie F. Dendritic cells in intestinal immune regulation. Nat Rev Immunol. 2008;8(6):435–46.
   PubMed Web of Science ®Google Scholar
• Trentham DE, Townes AS, Kang AH. Autoimmunity to type II collagen an experimental model of arthritis. J Exp Med. 1977;146(3):857–68.
   Google Scholar
• Thompson HS, Harper N, Bevan DJ, Staines NA. Suppression of collagen induced arthritis by oral administration of type II col-lagen: changes in immune and arthritic responses mediated by active peripheral suppression. Autoimmunity. 1993;16(3):189–99.
   PubMed Web of Science ®Google Scholar
• Khare SD, Krco CJ, Griffiths MM, Luthra HS, David CS. Oral administration of an immunodominant human collagen peptide modulates collagen-induced arthritis. J Immunol. 1995;155(7): 3653–9.
   Google Scholar
• Kim WU, Lee WK, Ryoo JW, Kim SH, Kim J, Youn J, et al. Suppression of collagen-induced arthritis by single administration of poly(lactic-co-glycolic acid) nanoparticles entrapping type II collagen: a novel treatment strategy for induction of oral toler-ance. Arthritis Rheum. 2002;46(4):1109–20.
   PubMedGoogle Scholar
• Min SY, Hwang SY, Park KS, Lee JS, Lee KE, Kim KW, et al. Induction of IL-10-producing CD4+CD25+ T cells in animal model of collagen-induced arthritis by oral administration of type II collagen. Arthritis Res Ther. 2004;6(3):R213–9.
   PubMed Web of Science ®Google Scholar
• Min SY, Park KS, Cho ML, Kong JW, Cho YG, Hwang SY, et al. Antigen-induced, tolerogenic CD11c+, CD11b+ dendritic cells are abundant in Peyer's patches during the induction of oral tolerance to type II collagen and suppress experimental collagen-induced arthritis. Arthritis Rheum. 2006;54(3):887–98.
   PubMedGoogle Scholar
• Garcia G, Komagata Y, Slavin AJ, Maron R, Weiner HL. Sup-pression of collagen-induced arthritis by oral or nasal adminis-tration of type II collagen. J Autoimmun. 1999;13(3):315–24.
   Google Scholar
• Myers LK, Brand DD, Ye XJ, Cremer MA, Rosloniec EF, Bodo M, et al. Characterization of recombinant type II collagen: ar-thritogenicity and tolerogenicity in DBA/1 mice. Immunology. 1998;95(4): 631–9.
   PubMed Web of Science ®Google Scholar
• Zhu P, Li XY, Wang HK, Jia JF, Zheng ZH, Ding J, et al. Oral administration of type-II collagen peptide 250-270 suppresses specific cellular and humoral immune response in collagen-induced arthritis. Cfin Immunol. 2007;122(1):75–84.
   Web of Science ®Google Scholar
• Khoury SJ, Hancock WW, Weiner HL. Oral tolerance to myelin basic protein and natural recovery from experimental autoim-mune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of trans-forming growth factor beta, interleukin 4, and prostaglandin E expression in the brain. J Exp Med. 1992;176(5):1355–64.
   Google Scholar
• Chen Y, Kuchroo VK, Inobe J, Hafler DA, Weiner HL. Regulatory T cell clones induced by oral tolerance: suppression of autoim-mune encephalomyelitis. Science. 1994;265(5176):1237–40.
   Google Scholar
• Santos LM, Al-Sabbagh A, Londono A, Weiner HL. Oral toler-ance to myelin basic protein induces regulatory TGF-beta-secreting T cells in Peyer's patches of SJL mice. Cell Immunol. 1994; 157(2):439–47.
   PubMed Web of Science ®Google Scholar
• Polanski M, Melican NS, Zhang J, Weiner HL. Oral adminis-tration of the immunodominant B-chain of insulin reduces dia-betes in a co-transfer model of diabetes in the NOD mouse and is associated with a switch from Thl to Th2 cytokines. J Autoim-mun. 1997;10(4):339–46.
   PubMed Web of Science ®Google Scholar
• Thorbecke GJ, Schwarcz R, Leu J, Huang C, Simmons WJ. Modulation by cytokines of induction of oral tolerance to type II collagen. Arthritis Rheum. 1999;42(1):110–8.
   Google Scholar
• Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med. 2003;198(12):1875–86.
   PubMed Web of Science ®Google Scholar
• Huber S, Schramm C, Lehr HA, Mann A, Schmitt S, Becker C, et al. Cutting edge: TGF-beta signaling is required for the in vivo expansion and immunosuppressive capacity of regulatory CD4+CD25+T cells. J Immunol. 2004;173(11):6526–31.
   PubMed Web of Science ®Google Scholar
• Pyzik M, Piccirillo CA. TGF-betal modulates Foxp3 expression and regulatory activity in distinct CD4+ T cell subsets. J Leukoc Biol. 2007;82(2):335–46.
   PubMed Web of Science ®Google Scholar
• Kitani A, Fuss I, Nakamura K, Kumaki F, Usui T, Strober W. Transforming growth factor (TGF)-betal-producing regulatory T cells induce Smad-mediated interleukin 10 secretion that facili-tates coordinated immunoregulatory activity and amelioration of TGF-betal-mediated fibrosis. J Exp Med. 2003;198(8):1179–88.
   PubMed Web of Science ®Google Scholar
• Fukaura H, Kent SC, Pietrusewicz MJ, Khoury SJ, Weiner HL, Hafler DA. Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-beta-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients. J Clin Invest. 1996;98(1):70–7.
   PubMed Web of Science ®Google Scholar
• Nakamura K, Kitani A, Strober W. Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J Exp Med. 2001;194(5):629–44.
   Google Scholar
• Yoshino S. Treatment with an anti-IL-4 monoclonal antibody blocks suppression of collagen-induced arthritis in mice by oral administration of type II collagen. J Immunol. 1998;160(6):3067–71.
   PubMed Web of Science ®Google Scholar
• Morita Y, Yang J, Gupta R, Shimizu K, Shelden EA, Endres J, et al. Dendritic cells genetically engineered to express IL-4 inhibit murine collagen-induced arthritis. J Clin Invest. 2001; 107(10):1275–84.
   PubMed Web of Science ®Google Scholar
• Kim SH, Kim S, Evans CH, Ghivizzani SC, Oligino T, Robbins PD. Effective treatment of established murine collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express IL-4. J Immunol. 2001;166(5):3499–505.
   PubMed Web of Science ®Google Scholar
• Wolvers DA, van der Cammen MJ, Kraal G. Mucosal tolerance is associated with, but independent of, up-regulation Th2 responses. Immunology. 1997;92(3):328–33.
   PubMed Web of Science ®Google Scholar
• Walmsley M, Katsikis PD, Abney E, Parry S, Williams RO, Maini RN, et al. Interleukin-10 inhibition of the progression of established collagen-induced arthritis. Arthritis Rheum. 1996;39(3):495–503.
   PubMed Web of Science ®Google Scholar
• Joosten LA, Lubberts E, Durez P, Helsen MM, Jacobs MJ, Goldman M, et al. Role of interleukin-4 and interleukin-10 in murine collagen-induced arthritis. Protective effect of interleu-kin-4 and interleukin-10 treatment on cartilage destruction. Arthritis Rheum. 1997;40(2):249–60.
   Google Scholar
• Kemper C, Chan AC, Green JM, Brett KA, Murphy KM, Atkinson JP. Activation of human CD4+ cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype. Nature. 2003;421(6921):388–92.
   PubMed Web of Science ®Google Scholar
• Slavin AJ, Maron R, Weiner HL. Mucosal administration of IL-10 enhances oral tolerance in autoimmune encephalomyelitis and diabetes. Int Immunol. 2001;13(6):825–33.
   Google Scholar
• Sato K, Suematsu A, Okamoto K, Yamaguchi A, Morishita Y, Kadono Y, et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med. 2006;203(12):2673–82.
   PubMed Web of Science ®Google Scholar
• Kolls JK, Linden A. Interleukin-17 family members and inflam-mation. Immunity. 2004;21(4):467–76.
   PubMed Web of Science ®Google Scholar
• Ju JH, Cho ML, Jhun JY, Park MJ, Oh H.T, Min SY, et al. Oral administration of type-II collagen suppresses IL-17-associated RANKL expression of CD4+ T cells in collagen-induced arthritis. Immunol Lett. 2008;117(1):16–25.
   Google Scholar
• Kelsall BL, Rescigno M. Mucosal dendritic cells in immunity and inflammation. Nat Immunol. 2004;5(11):1091–5.
   PubMed Web of Science ®Google Scholar
• Iwasaki A, Kelsall BL. Localization of distinct Peyer's patch dendritic cell subsets and their recruitment by chemokines mac-rophage inflammatory protein (MIP)-3alpha, MIP-3beta, and secondary lymphoid organ chemokine. J Exp Med. 2000; 191(8):1381–94.
   PubMed Web of Science ®Google Scholar
• Iwasaki A, Kelsall BL. Unique functions of CD b+, CD8 alpha+, and double-negative Peyer's patch dendritic cells. J Immunol. 2001;166(8):4884–90.
   PubMed Web of Science ®Google Scholar
• Castellaneta A, Abe M, Morelli AE, Thomson AW. Identification and characterization of intestinal Peyer's patch interferon-alpha producing (plasmacytoid) dendritic cells. Hum Immunol. 2004;65(2):104–13.
   PubMed Web of Science ®Google Scholar
• Ehirchiou D, Xiong Y, Xu G, Chen W, Shi Y, Zhang L. CD1 lb facilitates the development of peripheral tolerance by suppressing Th17 differentiation. J Exp Med. 2007;204(7):1519–24.
   PubMed Web of Science ®Google Scholar
• Jung YO, Min SY, Cho ML, Park MJ, Jeon JY, Lee JS, et al. CD8alpha+ dendritic cells enhance the antigen-specific CD4 + T-cell response and accelerate development of collagen-induced arthritis. Immunol Lett. 2007;111(2):76–83.
   PubMed Web of Science ®Google Scholar
• Bilsborough J, George TC, Norment A, Viney JL. Mucosal CD8alpha+ DC, with a plasmacytoid phenotype, induce differ-entiation and support function of T cells with regulatory prop-erties. Immunology. 2003;108(4):481–92.
   PubMed Web of Science ®Google Scholar
• Roncarolo MG, Gregori S, Battaglia M, Bacchetta R, Fleischhauer K, Levings MK. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev. 2006;212:28–50.
   PubMed Web of Science ®Google Scholar
• Fallarino F, Grohmann U, You S, McGrath BC, Cavener DR, Vacca C, et al. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J Immunol. 2006;176(11):6752–61.
   PubMed Web of Science ®Google Scholar
• Park MJ, Min SY, Park KS, Cho YG, Cho ML, Jung YO, et al. Indoleamine 2, 3-dioxygenase-expressing dendritic cells are involved in the generation of CD4+CD25+ regulatory T cells in Peyer's patches in an orally tolerized, collagen-induced arthritis mouse model. Arthritis Res Ther. 2008;10(1):R11.
   PubMed Web of Science ®Google Scholar
• Iwata M, Hirakiyama A, Eshima Y, Kagechika H, Kato C, Song SY. Retinoic acid imprints gut-homing specificity on T cells. Immunity. 2004;21(4):527–38.
   PubMed Web of Science ®Google Scholar
• Stagg AJ, Kamm MA, Knight SC. Intestinal dendritic cells increase T cell expression of alpha4beta7 integrin. Eur J Immu-nol. 2002;32(5):1445–54.
   Google Scholar
• Agace WW. T-cell recruitment to the intestinal mucosa. Trends Immunol. 2008;29(10:514–22.
   PubMedGoogle Scholar
• Mora JR, Bono MR, Manjunath N, Weninger W, Cavanagh LL, Rosemblatt M, et al. Selective imprinting of gut-homing T cells by Peyer's patch dendritic cells. Nature. 2003;424(6944):88–93.
   PubMed Web of Science ®Google Scholar
• Siewert C, Menning A, Dudda J, Siegmund K, Lauer U, Floess S, et al. Induction of organ-selective CD4+ regulatory T cell homing. Eur J Immunol. 2007;37(4):978–89.
   PubMed Web of Science ®Google Scholar
• Kang SG, Lim HW, Andrisani OM, Broxmeyer HE, Kim CH. Vitamin A metabolites induce gut-homing FoxP3+ regulatory T cells. J Immunol. 2007;179(6):3724–33.
   Google Scholar
• Coombes JL, Siddiqui KR, Arancibia-Carcamo CV, Hall J, Sun CM, Belkaid Y, et al. A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism. J Exp Med. 2007;204(8):1757–64.
   Google Scholar
• Mucida D, Park Y, Kim G, Turovskaya 0, Scott I, Kronenberg M, et al. Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science. 2007;317(5835):256–60.
   Google Scholar
• Benson MJ, Pino-Lagos K, Rosemblatt M, Noelle RJ. All-trans retinoic acid mediates enhanced T reg cell growth, differentia-tion, and gut homing in the face of high levels of co-stimulation. J Exp Med. 2007;204(8):1765–74.
   PubMed Web of Science ®Google Scholar
• Sun CM, Hall JA, Blank RB, Bouladoux N, Oukka M, Mora JR, et al. Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 T reg cells via retinoic acid. J Exp Med. 2007;204(8):1775–85.
   PubMed Web of Science ®Google Scholar
• Denning TL, Wang YC, Patel SR, Williams IR, Pulendran B. Lamina propria macrophages and dendritic cells differentially induce regulatory and interleukin 17-producing T cell responses. Nat Immunol. 2007;8(10):1086–94.
   Google Scholar
• Mora JR, Iwata M, Eksteen B, Song SY, Junt T, Senman B, et al. Generation of gut-homing IgA-secreting B cells by intestinal dendritic cells. Science. 2006;314(5802):1157–60.
   PubMed Web of Science ®Google Scholar
• Tsuji NM, Kosaka A. Oral tolerance: intestinal homeostasis and antigen-specific regulatory T cells. Trends Immunol. 2008;29(11):532–40.
   PubMed Web of Science ®Google Scholar
• Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell. 2008;133(5):775–87.
   PubMed Web of Science ®Google Scholar
• Vignali DA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol. 2008;8(7):523–32.
   PubMed Web of Science ®Google Scholar
• Dieckmann D, Bruett CH, Ploettner H, Lutz MB, Schuler G. Human CD4(+)CD25(+) regulatory, contact-dependent T cells induce interleukin 10-producing, contact-independent type 1-like regulatory T cells [corrected]. J Exp Med. 2002;196(2):247–53.
   Google Scholar
• Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature. 2007;450(7169):566–9.
   PubMed Web of Science ®Google Scholar
• Coffer PJ, Burgering BM. Forkhead-box transcription factors and their role in the immune system. Nat Rev Immunol. 2004; 4(11):889–99.
   PubMed Web of Science ®Google Scholar
• Mills KH. Regulatory T cells: friend or foe in immunity to infection? Nat Rev Immunol. 2004;4(11):841–55.
   PubMed Web of Science ®Google Scholar
• Fantini MC, Becker C, Monteleone G, Pallone F, Galle PR, Neurath MF. Cutting edge: TGF-beta induces a regulatory phe-notype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7. J Immunol. 2004;172(9):5149–53.
   PubMed Web of Science ®Google Scholar
• Vlad G, Cortesini R, Suciu-Foca N. License to heal: bidirectional interaction of antigen-specific regulatory T cells and tolerogenic APC. J Immunol. 2005;174(10):5907–14.
   Google Scholar
• Cederbom L, Hall H, Ivars F. CD4+CD25+ regulatory T cells down-regulate co-stimulatory molecules on antigen-presenting cells. Eur J Immunol. 2000;30(6):1538–43.
   Google Scholar
• Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science. 2008;322(5899):271–5.
   Google Scholar
• Huang CT, Workman CJ, Flies D, Pan X, Marson AL, Zhou G, et al. Role of LAG-3 in regulatory T cells. Immunity. 2004;21(4):503–13.
   PubMed Web of Science ®Google Scholar
• Workman CJ, Vignali DA. The CD4-related molecule, LAG-3 (CD223), regulates the expansion of activated T cells. Eur J Immunol. 2003;33(4):970–9.
   PubMed Web of Science ®Google Scholar
• Fallarino F, Grohmann U, Hwang KW, Orabona C, Vacca C, Bianchi R, et al. Modulation of tryptophan catabolism by regu-latory T cells. Nat Immunol. 2003;4(12):1206–12.
   PubMed Web of Science ®Google Scholar
• Grohmann U, Volpi C, Fallarino F, Bozza S, Bianchi R, Vacca C, et al. Reverse signaling through GITR ligand enables dexamethasone to activate IDO in allergy. Nat Med. 2007; 13(5):579–86.
   PubMed Web of Science ®Google Scholar
• Puccetti P, Grohmann U. IDO and regulatory T cells: a role for reverse signalling and non-canonical NF-kappaB activation. Nat Rev Immunol. 2007;7(10):817–23.
   PubMed Web of Science ®Google Scholar
• Thompson SJ, Thompson HS, Harper N, Day MJ, Coad AJ, Elson CJ, et al. Prevention of pristane-induced arthritis by the oral administration of type II collagen. Immunology. 1993;79(1):152–7.
   PubMed Web of Science ®Google Scholar
• Yoshino S. Downregulation of silicone-induced chronic arthritis by gastric administration of type II collagen. Immunopharma-cology. 1995;31(1):103–8.
   PubMedGoogle Scholar
• Ding CH, Li Q, Xiong ZY, Zhou AW, Jones G, Xu SY. Oral administration of type II collagen suppresses pro-inflammatory mediator production by synoviocytes in rats with adjuvant arthritis. Clin Exp Immunol. 2003;132(3):416–23.
   PubMed Web of Science ®Google Scholar
• Barnett ML, Kremer JM, St Clair EW, Clegg DO, Furst D, Weisman M, et al. Treatment of rheumatoid arthritis with oral type II collagen. Results of a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 1998;41(2):290–7.
   PubMedGoogle Scholar
• Ausar SF, Beltramo DM, Castagna LF, Quintana S, Silvera E, Kalayan G, et al. Treatment of rheumatoid arthritis by oral administration of bovine tracheal type II collagen. Rheumatol Int. 2001;20(4):138–44.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Antivalle M, Sarzi-Puttini P, Dell'Acqua D, Panni B, Caruso I. Oral type II collagen in the treatment of rheumatoid arthritis. A six-month double blind placebo-controlled study. Clin Exp Rheumatol. 2000;18(5):571–7.
   Google Scholar
• McKown KM, Carbone LD, Kaplan SB, Aelion JA, Lohr KM, Cremer MA, et al. Lack of efficacy of oral bovine type II collagen added to existing therapy in rheumatoid arthritis. Arthritis Rheum. 1999;42(6):1204–8.
   PubMed Web of Science ®Google Scholar
• Barnett ML, Combitchi D, Trentham DE. A pilot trial of oral type II collagen in the treatment of juvenile rheumatoid arthritis. Arthritis Rheum. 1996;39(4):623–8.
   PubMedGoogle Scholar
• Sieper J, Kary S, Sorensen H, Alten R, Eggens U, Huge W, et al. Oral type II collagen treatment in early rheumatoid arthritis. A double-blind, placebo-controlled, randomized trial. Arthritis Rheum. 1996;39(1):41–51.
   PubMedGoogle Scholar
• Trentham DE, Dynesius-Trentham RA, Orav EJ, Combitchi D, Lorenzo C, Sewell KL, et al. Effects of oral administration of type II collagen on rheumatoid arthritis. Science. 1993; 261(5129):1727–30.
   PubMed Web of Science ®Google Scholar
• Choy EH, Scott DL, Kingsley GH, Thomas S, Murphy AG, Staines N, et al. Control of rheumatoid arthritis by oral tolerance. Arthritis Rheum. 2001;44(9):1993–7.
   PubMed Web of Science ®Google Scholar
• Hanson DG, Roy MJ, Green GM, Miller SD. Inhibition of orally-induced immune tolerance in mice by prefeeding an endopepti-dase inhibitor. Reg Immunol. 1993;5(2):76–84.
   PubMedGoogle Scholar
• Bjamason I, Williams P, So A, Zanelli GD, Levi AJ, Gumpel JM, et al. Intestinal permeability and inflammation in rheumatoid arthritis: effects of non-steroidal anti-inflammatory drugs. Lancet. 1984;2(8413):1171–4.
   PubMed Web of Science ®Google Scholar
• Bjamason I, Zanelli G, Smith T, Prouse P, Williams P, Smethurst P, et al. Nonsteroidal antiinflammatory drug-induced intestinal inflammation in humans. Gastroenterology. 1987;93(3):480–9.
   PubMed Web of Science ®Google Scholar
• Scheuer WV, Hobbs MV, Weigle WO. Interference with toler-ance induction in vivo by inhibitors of prostaglandin synthesis. Cell Immunol. 1987;104(2):409–18.
   Google Scholar
• Louis E, Franchimont D, Deprez M, Lamproye A, Schaaf N, Mahieu P, et al. Decrease in systemic tolerance to fed ovalbumin in indomethacin-treated mice. Int Arch Allergy Immunol. 1996;109(1):21–6.
   PubMed Web of Science ®Google Scholar
• Morteau 0. COX-2: promoting tolerance. Nat Med. 1999; 5(8):867–8.
   Google Scholar
• Takagi H, Hiroi T, Yang L, Takamura K, Ishimitsu R, Kawauchi H, et al. Efficient induction of oral tolerance by fusing cholera toxin B subunit with allergen-specific T-cell epitopes accumu-lated in rice seed. Vaccine. 2008;26(48):6027–30.
   PubMed Web of Science ®Google Scholar
• Sun JB, Raghavan S, Sjoling A, Lundin S, Holmgren J. Oral tolerance induction with antigen conjugated to cholera toxin B subunit generates both Foxp3+CD25+ and Foxp3-CD25-CD4+ regulatory T cells. J Immunol. 2006;177(11):7634–44.
   Google Scholar
• Bregenholt S, Wang M, Wolfe T, Hughes A, Baerentzen L, Dyrberg T, et al. The cholera toxin B subunit is a mucosal adjuvant for oral tolerance induction in type 1 diabetes. Scand J Immunol. 2003;57(5):432–8.
   PubMed Web of Science ®Google Scholar
• Kim N, Cheng KC, Kwon SS, Mora R, Barbieri M, Yoo TJ. Oral administration of collagen conjugated with cholera toxin induces tolerance to type II collagen and suppresses chondritis in an animal model of autoimmune ear disease. Ann Otol Rhino' Laryngol. 2001;110[7 Pt 1]:646–54.
   Google Scholar